GlassScriptPhysician profile
Cassandra Green
NPI 1316580657
$3,478.55
in general payments reported to CMS, 2019-2025
36 companies · $1,692 in 2025
The $1,692 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $169 · 2023: $111 · 2024: $1,506 · 2025: $1,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,309.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $954.13 | 2024-2025 | |
| Lilly USA, LLC | $265.13 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $260.06 | 2024-2025 | Trelegy Ellipta, Bexsero, Pediarix |
| Astrazeneca Pharmaceuticals LP | $212.19 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $180.01 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $161.06 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $148.27 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $140.30 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $121.02 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $110.41 | 2022-2024 | Xarelto |
| Shield Therapeutics INC | $104.82 | 2024 | |
| Medtronic, INC. | $87.69 | 2025 | Intellis Adaptivestim |
| Otsuka America Pharmaceutical, INC. | $74.39 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Amgen INC. | $67.19 | 2024-2025 | Repatha, Otezla, Repatha |
| Lundbeck LLC | $49.11 | 2022-2025 | Rexulti |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.